Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGXOTCMKTS:EKTAYNASDAQ:GHNASDAQ:NTRANYSE:NVTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$178.85+1.3%$176.47$136.99▼$182.38$19.75B0.49991,650 shs436,517 shsEKTAYElekta$5.19+0.4%$5.12$4.36▼$7.13$1.99B1.26,808 shs3,536 shsGHGuardant Health$50.25+0.1%$45.45$20.14▼$53.42$6.26B1.442.17 million shs956,932 shsNTRANatera$161.500.0%$160.34$92.14▼$183.00$22.09B1.731.43 million shs468,868 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics0.00%+0.63%+3.00%+9.00%+26.93%EKTAYElekta0.00%+2.98%+0.87%+9.73%-20.15%GHGuardant Health0.00%-1.20%+3.80%+23.83%+76.87%NTRANatera0.00%-3.85%-2.42%+20.64%+44.66%NVTAInvitae0.00%0.00%0.00%0.00%-57.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDGXQuest Diagnostics4.9386 of 5 stars2.34.04.24.72.92.52.5EKTAYElekta3.2881 of 5 stars0.05.01.70.02.31.71.9GHGuardant Health3.8504 of 5 stars2.51.00.04.43.82.50.6NTRANatera2.1396 of 5 stars2.52.00.00.03.42.50.6NVTAInvitaeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.69Moderate Buy$185.733.85% UpsideEKTAYElekta 2.00HoldN/AN/AGHGuardant Health 3.00Buy$53.766.99% UpsideNTRANatera 3.00Buy$184.6314.32% UpsideNVTAInvitae 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GH, EKTAY, NTRA, NVTA, and DGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.006/3/2025EKTAYElektaDanskeSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.005/6/2025DGXQuest DiagnosticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$180.00 ➝ $190.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.005/1/2025GHGuardant HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $65.005/1/2025GHGuardant HealthTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $60.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$9.87B2.02$13.65 per share13.10$61.38 per share2.91EKTAYElekta$1.71B1.17$0.61 per share8.48$2.19 per share2.37GHGuardant Health$739.02M8.42N/AN/A($1.13) per share-44.47NTRANatera$1.70B13.00N/AN/A$9.05 per share17.85NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$7.9122.6117.052.478.81%15.11%6.65%7/22/2025 (Estimated)EKTAYElekta$22.37M$0.05103.8212.07N/A1.15%11.55%3.75%8/27/2025 (Estimated)GHGuardant Health-$436.37M-$3.39N/AN/AN/A-53.82%N/A-26.77%8/6/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ALatest GH, EKTAY, NTRA, NVTA, and DGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025DGXQuest Diagnostics$2.56N/AN/AN/A$2.73 billionN/A5/28/2025Q4 2025EKTAYElekta$0.13$0.11-$0.02-$0.10$507.19 million$503.22 million5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million4/22/2025Q1 2025DGXQuest Diagnostics$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.79%N/A40.46%14 YearsEKTAYElekta$0.122.31%N/A240.00%N/AGHGuardant HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ALatest GH, EKTAY, NTRA, NVTA, and DGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/14/2025DGXQuest Diagnosticsquarterly$0.801.86%7/7/20257/7/20257/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.841.441.31EKTAYElekta0.701.090.86GHGuardant HealthN/A4.113.76NTRANateraN/A3.873.74NVTAInvitaeN/A2.392.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EKTAYElektaN/AGHGuardant Health92.60%NTRANatera99.90%NVTAInvitae61.28%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics8.16%EKTAYElekta41.28%GHGuardant Health6.10%NTRANatera7.60%NVTAInvitae0.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics56,000111.64 million102.53 millionOptionableEKTAYElekta4,718383.57 million225.23 millionNot OptionableGHGuardant Health2,021123.89 million116.33 millionNot OptionableNTRANatera4,434136.55 million126.17 millionOptionableNVTAInvitae1,700267.01 million284.37 millionOptionableGH, EKTAY, NTRA, NVTA, and DGX HeadlinesRecent News About These CompaniesInvitae Corp (OTC:NVTA) Stock, Insider Trading ActivityOctober 3, 2024 | benzinga.comLabcorp completes acquisition of select assets of InvitaeAugust 6, 2024 | pharmabiz.comPInvitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy PatientsJuly 22, 2024 | finance.yahoo.comKirkland Cleared to Represent Invitae After Conflict ObjectionsMay 7, 2024 | news.bloomberglaw.comNInvitae's $239 million sale to Labcorp approved by Bankruptcy CourtMay 7, 2024 | bizjournals.comLabcorp Makes Another Acquisition, Plucking Invitae Assets From Bankruptcy AuctionApril 29, 2024 | medcitynews.comMLabCorp On the Verge of Acquiring Invitae’s AssetsApril 29, 2024 | mddionline.comMLabcorp to acquire Invitae in strategic dealApril 28, 2024 | msn.comKirkland Defends Invitae Representation Amid Conflict ClaimsApril 26, 2024 | news.bloomberglaw.comNLabcorp picks up Invitae portfolio for $239M in bankruptcy saleApril 26, 2024 | fiercebiotech.comFLabcorp to acquire Invitae assets for $239 millionApril 26, 2024 | uk.investing.comLabcorp wins $239M bid for bankrupt InvitaeApril 26, 2024 | bizjournals.comLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealApril 25, 2024 | msn.comInvitae Corporation: Invitae Enters into Agreement with Labcorp for Sale of BusinessApril 25, 2024 | finanznachrichten.deLabcorp Acquiring Invitae Assets for $239M, Posts 5 Percent Rise in Q1 RevenuesApril 25, 2024 | 360dx.com3Labcorp to Buy Assets of Bankrupt Invitae for $239MApril 25, 2024 | marketwatch.comClinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mlnApril 24, 2024 | reuters.comInvitae Enters into Agreement with Labcorp for Sale of BusinessApril 24, 2024 | finance.yahoo.comLabcorp Announces Winning Bid for Select Assets of InvitaeApril 24, 2024 | prnewswire.comInvitae Publishes its Environmental, Social and Governance (ESG) ReportApril 22, 2024 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks3 Stocks With Near-Unanimous Buys That Could Rally HigherBy Nathan Reiff | July 2, 2025View 3 Stocks With Near-Unanimous Buys That Could Rally HigherGH, EKTAY, NTRA, NVTA, and DGX Company DescriptionsQuest Diagnostics NYSE:DGX$178.85 +2.25 (+1.27%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$177.79 -1.06 (-0.59%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Elekta OTCMKTS:EKTAY$5.19 +0.02 (+0.39%) As of 07/3/2025 12:57 PM EasternElekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.Guardant Health NASDAQ:GH$50.25 +0.07 (+0.14%) Closing price 07/3/2025 02:58 PM EasternExtended Trading$50.50 +0.25 (+0.50%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Natera NASDAQ:NTRA$161.50 -0.07 (-0.04%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$161.50 0.00 (0.00%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
